In brief: Eli Lilly invests $400m in manufacturing

Eli Lilly intends to invest $400 million in its manufacturing facilities in Indianapolis to help meet demand and provide additional capacity for future medicines.

The investment will also provide technology upgrades to the active ingredient, syringe filling, device assembly and packaging operations at the Lilly Technology Centre campus.

Since 2012, Lilly has invested over $5 billion in the US, with the majority in its Indiana facilities.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Related news

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...